Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets

Subsets of Myeloid-Derived Suppressor Cells

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

The induction of CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSCs) is an important immune-evading mechanism used by tumors. However, the exact nature and function of MDSCs remain elusive, especially because they constitute a heterogeneous population that has not yet been clearly defined. Here, we identified 2 distinct MDSC subfractions with clear morphologic, molecular, and functional di...

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented...

Myeloid-derived Suppressor Cells in Glioblastoma Patients - Phenotype, Function and Clinical Relevance

Estrogens drive myeloid-derived suppressor cell accumulation